Last $15.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/18/14 All times are local (Market data is delayed by at least 15 minutes).

vistagen therapeutics inc (VSTAD) Snapshot

Open
$15.00
Previous Close
$15.00
Day High
$15.00
Day Low
$15.00
52 Week High
09/24/13 - $17.80
52 Week Low
10/17/13 - $5.00
Market Cap
19.2M
Average Volume 10 Days
64.0
EPS TTM
$-6.20
Shares Outstanding
1.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VISTAGEN THERAPEUTICS INC (VSTAD)

Related News

No related news articles were found.

vistagen therapeutics inc (VSTAD) Related Businessweek News

No Related Businessweek News Found

vistagen therapeutics inc (VSTAD) Details

VistaGen Therapeutics, Inc., a biotechnology company, focuses on application and development of proprietary human pluripotent stem cell technology for drug rescue and regenerative medicine in the United States. The company is involved in the development of CardioSafe 3D, an in vitro bioassay system for assessing new drug candidates for potential cardiac toxicity before they are tested in animals or humans; and LiverSafe 3D, an in vitro bioassay system for potential drug-induced liver toxicity. It is also engaged in the development of AV-101, a prodrug candidate for the treatment of neuropathic pain, epilepsy, and depression that has completed Phase I development. In addition, the company focuses on Human Clinical Trials in a Test Tube, a stem cell technology platform for controlling the differentiation of human pluripotent stem cells into various types of mature, functional, and adult human cells. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

10 Employees
Last Reported Date: 07/29/14
Founded in 1998

vistagen therapeutics inc (VSTAD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
Founder, President, Chief Scientific Officer ...
Total Annual Compensation: --
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

vistagen therapeutics inc (VSTAD) Key Developments

VistaGen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

VistaGen Therapeutics, Inc. filed its 10-K on Jun 25, 2014 for the period ending Mar 31, 2014. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

VistaGen Therapeutics, Inc. Adopts Amended and Restated Bylaws

On February 5, 2014, the Board of Directors of VistaGen Therapeutics, Inc. unanimously approved and adopted the Amended and Restated Bylaws of the Company, which Amended and Restated Bylaws replace the Company's previous bylaws in their entirety.

VistaGen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

VistaGen Therapeutics, Inc. filed its 10-K on Jul 18, 2013 for the period ending Mar 31, 2013. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSTAD:US $15.00 USD 0.00

VSTAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSTAD.
View Industry Companies
 

Industry Analysis

VSTAD

Industry Average

Valuation VSTAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VISTAGEN THERAPEUTICS INC, please visit www.vistagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.